Atopic dermatitis (AD) is a frequent, chronic remittent skin disease. The pathophysiology of
AD has been increasingly understood within the last years, which may help to identify …

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The
prevalence of AD is increasing and is currently estimated at 10–20% in adults worldwide. In …

Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous
and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved …

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense
pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a …

Dupilumab is a monoclonal antibody that represents the first approved targeted biological
therapy for adults, adolescents, and children older than 6 years with moderate-to-severe …

The evolving discoveries in atopic dermatitis (AD) broaden our understanding of the
pathogenesis of the disease and, above all, enable better management for patients …

Atopic dermatitis (AD) is a prevalent inflammatory skin disorder affecting all age and ethnic
groups. The age-dependent varying appearance and extent of pruritic lesions are …

Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children
and adults in industrialized countries. Up to one-third of adults (probably a smaller …

Atopic dermatitis (AD) is a chronic, systemic disease that has a multifactorial etiology, where
immune system disorders and epidermal barrier dysfunction are added to the influence of …

Background Real-life data on long-term effectiveness and safety of dupilumab in atopic
dermatitis patients are limited. Objective To study 52-week effectiveness and safety of …